13F Holdings
中文EN

AVCRF Avricore Health Inc. IFRS

Pharmaceutical Preparations · OTC · SEC CIK 1355736 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY33.7%
TTM net income YoY4.6%
TTM EPS YoY0.0%
Revenue 3-yr CAGR236.0%
Net income 3-yr CAGR—

Margins

Gross margin40.4%
Operating margin—
Net margin-14.4%
FCF margin17.7%
EBITDA margin—

Returns

ROE-33.6%
ROA-27.7%
ROIC (approx.)—
Asset turnover1.93x

Leverage & solvency

Liabilities / assets14.4%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.50x
Accruals ratio-69.2%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31FY20202020-12-31
Income statement
Revenue4.66M3.48M1.77M122,80833,030
Cost of revenue2.91M2.28M1.31M92,28715,550
Gross profit1.88M1.20M456,79330,52117,480
SG&A expense409,398339,369250,144182,847114,227
Interest expense———38,438158,952
Pretax income129,001-693,253-817,945-1.75M—
Net income-668,977-701,215-818,228-1.71M-1.17M
EPS (basic)-0.01-0.01-0.01-0.02-0.02
EPS (diluted)-0.01-0.01-0.01-0.02—
Weighted avg. shares (diluted)100.31M99.56M97.86M——
Balance sheet
Cash & equivalents1.13M276,571620,5272.01M302,715
Receivables419,587427,689770,37391,54811,928
Inventory50720,676———
Current assets1.58M773,5611.43M2.16M440,087
PP&E, netmay include right-of-use assets (IFRS)656,4411.72M1.11M90,8750
Intangibles——29,861——
Total assets2.30M2.54M2.57M2.28M440,090
Current liabilities——604,893——
Total liabilities330,817529,218604,89384,4771.15M
Shareholders' equity1.97M2.01M1.96M2.20M-724,041
Cash flow statement
Operating cash flow1.00M660,403-437,832-1.23M-1.22M
Capital expenditure181,0941.02M1.19M105,358—
Free cash flow823,521-361,168-1.63M-1.34M—
Investing cash flow-205,347-1.05M-1.21M-140,3640
Financing cash flow56,60042,500253,8803.08M1.51M
Depreciation & amortization3,1372,34763117,9840
Stock-based compensation541,164703,612331,522495,791130,219

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.